This is a significant regulatory milestone that increases the likelihood of tinlarebant becoming the first approved treatment for Stargardt disease. Traders should monitor FDA feedback and the completion of the NDA review process, as approval could drive substantial valuation upside. Consider positioning ahead of potential PDUFA date announcements.
Price Chart
Executive Summary
Belite Bio announced the initiation of a rolling submission of a New Drug Application (NDA) to the FDA for tinlarebant, an investigational therapy for Stargardt disease type 1, supported by Breakthrough Therapy Designation. The company expects to complete the submission in Q2 2026.
Key Facts
- Belite Bio initiated a rolling NDA submission to the FDA for tinlarebant for the treatment of Stargardt disease type 1 (STGD1).
- The NDA submission is supported by Breakthrough Therapy Designation and data from the Phase 3 DRAGON trial.
- The company expects to complete the submission in Q2 2026.
- Tinlarebant has also received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA.
- Management is advancing commercialization planning in anticipation of a potential U.S. launch.
Financial Impact
No immediate financial impact disclosed, but regulatory progress increases the probability of future revenue from potential approval and commercialization.
Risk Factors
- FDA may require additional data or reject the NDA, delaying or preventing approval.
- Clinical data may not be sufficient to support approval despite Breakthrough Therapy Designation.
- Commercialization timelines and market adoption remain uncertain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-045989 |
| Document: tm2611999d1_6k.htm | 0001104659-26-045989 |
| Document: 0001104659-26-045989-index-headers.html | 0001104659-26-045989 |
| Document: 0001104659-26-045989-index.html | 0001104659-26-045989 |
| Document: 0001104659-26-045989.txt | 0001104659-26-045989 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 6-K | $147.34 | awaiting T+20 | — | $147.33 (−0.01%) |
Sep 9, 2026 6w ago | Insider Cluster | $175.07 $152.52 | ▲ +12.88% | ▲ +15.01% | $147.33 (+15.85%) |
Aug 12, 2026 10w ago | 6-K | $166.28 $173.79 | ▲ +4.52% | ▲ +6.26% | $147.33 (−11.40%) |
Aug 12, 2026 10w ago | Press Release | $166.28 $173.79 | ▲ +4.52% | ▲ +6.26% | $147.33 (−11.40%) |
Jun 12, 2026 19w ago | 6-K | $144.24 $147.03 | ▲ +1.93% | ▲ +2.68% | $147.33 (+2.14%) |
May 20, 2026 22w ago | Press Release | $143.36 $146.12 | ▲ +1.93% | ▲ +1.18% | $147.33 (+2.77%) |
Apr 21, 2026 26w ago | 6-K | $167.42 $139.70 | ▼ −16.56% | ▼ −19.72% | $147.33 (−12.00%) |
Apr 21, 2026 26w ago | Press Release | $167.42 $139.70 | ▼ −16.56% | ▼ −19.72% | $147.33 (−12.00%) |
Apr 9, 2026 28w ago | Insider Cluster | $181.17 $156.21 | ▲ +13.78% | ▲ +21.34% | $147.33 (+18.68%) |
Apr 9, 2026 28w ago | Insider Cluster | $181.17 $156.21 | ▲ +13.78% | ▲ +21.34% | $147.33 (+18.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers